Chris Bond

Chris Bond

Company: Notch Therapeutics

Job title: Senior Vice President Pre-Clinical & Translational Sciences


Towards the Development of Multiplexed Cellular Therapies: The Promise of iPSC Derived T-cell Products 4:00 pm

Design of effective allogeneic cell therapies requires multiplexed engineering. Clinical success in solid tumor settings will require multiple mechanisms of action. Stem Cell derived products enable identification and expansion of engineered products without deleterious off target damage. Control of Notch signaling is critical for lineage commitment and differentiation potential of developing T-cellsRead more

day: Day 1 - Track A - Post Lunch

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.